Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China
NCT ID: NCT04853238
Last Updated: 2024-12-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1507 participants
OBSERVATIONAL
2021-04-27
2023-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Participants with stable disease
Prospective observational cohort study
Prospective observational cohort study. No study treatment was administered in this study.
Cohort 2: Participants with moderate acute exacerbation not requiring hospitalization
Prospective observational cohort study
Prospective observational cohort study. No study treatment was administered in this study.
Cohort 3: Participants requiring hospitalization for an acute exacerbation
Prospective observational cohort study
Prospective observational cohort study. No study treatment was administered in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prospective observational cohort study
Prospective observational cohort study. No study treatment was administered in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of COPD confirmed by spirometry (According to Global initiative for chronic obstructive lung disease \[GOLD\] 2019 criteria) in Tier 2 and Tier 3 hospitals.
* In hospitalized participants, recruit only participants who receive any intravenous therapy.
* A signed and dated written informed consent.
* Participants can communicate normally.
Exclusion Criteria
* Other unstable diseases or cognitive behavior, which could influence CAT and lung function results (judged by physicians).
* Experienced a moderate/severe COPD exacerbation treated by a physician within last 1 month.
* Currently participating in another COPD clinical study, which provides the participant investigational medication and/or disease management.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Huizhou, Guangdong, China
GSK Investigational Site
Jiangmen, Guangdong, China
GSK Investigational Site
Shaoguan, Guangdong, China
GSK Investigational Site
Shenzhen, Guangdong, China
GSK Investigational Site
Nanning, Guangxi, China
GSK Investigational Site
Wuhan, Hubei, China
GSK Investigational Site
Shenyang, Liaoning, China
GSK Investigational Site
Yinchuan, Ningxia, China
GSK Investigational Site
Xi'an, Shaanxi, China
GSK Investigational Site
Jinan, Shandong, China
GSK Investigational Site
Jinan, Shandong, China
GSK Investigational Site
Taiyuan, Shanxi, China
GSK Investigational Site
Zhejiang, Zhejiang, China
GSK Investigational Site
Beijing, , China
GSK Investigational Site
Beijing, , China
GSK Investigational Site
Cangzhou, , China
GSK Investigational Site
Chengdu, , China
GSK Investigational Site
Chongqing, , China
GSK Investigational Site
Chongqing, , China
GSK Investigational Site
Hangzhou, , China
GSK Investigational Site
Hefei, , China
GSK Investigational Site
Jingzhou, , China
GSK Investigational Site
Luoyang, , China
GSK Investigational Site
Nanchang, , China
GSK Investigational Site
Nanning, , China
GSK Investigational Site
Nanyang, , China
GSK Investigational Site
Pingdingshan, , China
GSK Investigational Site
Shanghai, , China
GSK Investigational Site
Shanghai, , China
GSK Investigational Site
Shanxi, , China
GSK Investigational Site
Shenyang, , China
GSK Investigational Site
Tianjin, , China
GSK Investigational Site
Tianjin, , China
GSK Investigational Site
Wuhan, , China
GSK Investigational Site
Xi'an, , China
GSK Investigational Site
Xiangtan, , China
GSK Investigational Site
Yibin, , China
GSK Investigational Site
Yibin, , China
GSK Investigational Site
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
213550
Identifier Type: -
Identifier Source: org_study_id